TABLE 3.
| Testing results |
CDC’s NBCCEDPa |
KPNCb |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Screened within the past 5 y |
Rarely, never, or unknown screening (combined) |
Rarely or never screened |
Unknown screening |
||||||||
| HPV | Cytology | Immediate CIN3+ risk (%) |
95% CI (%) | Immediate CIN3+ risk (%) |
95% CI (%) | Immediate CIN3+ risk (%) |
95% CI (%) | Immediate CIN3+ risk (%) |
95% CI (%) | Immediate CIN3+ risk (%) |
95% CI (%) |
| Positive | HSIL+ | 49.6 | (45.8–53.4) | 64.1 | (60.8–67.3) | 65.4 | (61.6–69.2) | 60.4 | (54.1–66.8) | 48.9 | (47.2–50.6) |
| AGC | 29.4 | (23.4–35.4) | 41.6 | (35.0–48.2) | 45.3 | (37.3–53.3) | 33.3 | (22.0–44.7) | 26.3 | (23.3–29.3) | |
| ASC-H | 25.2 | (21.4–28.9) | 30.6 | (25.7–35.4) | 33.8 | (28.0–39.7) | 22.2 | (13.9–30.5) | 25.7 | (24.2–27.3) | |
| LSIL | 4.1 | (3.4–4.8) | 6.2 | (5.1–7.2) | 5.2 | (4.1–6.3) | 8.4 | (6.3–10.6) | 4.3 | (4.0–4.6) | |
| ASC-US | 4.5 | (4.1–4.9) | 6.6 | (6.0–7.2) | 6.7 | (5.9–7.4) | 6.5 | (5.4–7.7) | 4.4 | (4.2–4.7) | |
| NILM | 2.4 | (1.8–2.9) | 3.5 | (2.7–4.4) | 3.6 | (2.5–4.6) | 3.3 | (1.9–4.7) | 2.1 | (2.0–2.3) | |
| Negative | HSIL+ | 32.0 | (21.4–42.6) | 47.8 | (38.0–57.7) | 50.0 | (38.8–61.2) | 41.0 | (21.0–60.9) | 25.2 | (18.5–31.9) |
| AGC | 3.0 | (1.6–4.3) | 7.0 | (4.6–9.5) | 7.6 | (4.8–10.5) | 5.1 | (0.8–9.5) | 1.1 | (0.6–1.5) | |
| ASC-H | 4.9 | (2.3–7.5) | 4.7 | (1.5–7.8) | 5.1 | (1.4–8.8) | 2.9 | (0.0–8.6) | 3.4 | (2.1– 4.8) | |
| LSIL | 1.0 | (0.3–1.7) | 1.2 | (0.2–2.1) | 0.8 | (0.0–1.8) | 2.0 | (0.0–4.2) | 1.1 | (0.6–1.5) | |
| ASC-US | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 | (0.0–0.1) | |
| NILM | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 | (0.0–0.0) | |
AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CIN3, cervical intraepiethial neoplasia grade III or greater; HSIL, high-grade squamous intraepithelial lesion; HSIL HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; KPNC, Kaiser Permanente Northern California; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy.
CDC population is at the age of 30 to 64 years who have an HPV test result, which includes primary Papanicolaou test results of ASC-US triaged by HPV
KPNC population is at the age of 25 to 65 years who underwent HPV cotesting. Risk estimates are from Egemen et al.9